Cellectis Overview

  • Year Founded
  • 1999

Year Founded

  • Status
  • Public

  • Employees
  • 229

Employees

  • Stock Symbol
  • ALCLS

Stock Symbol

  • Investments
  • 4

  • Share Price
  • $1.00
  • (As of Friday Closing)

Cellectis General Information

Description

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 8 rue de la Crolx Jarry
  • 75013 Paris
  • France
+33 01
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
PAR
Vertical(s)
Corporate Office
  • 8 rue de la Crolx Jarry
  • 75013 Paris
  • France
+33 01

Cellectis Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cellectis Stock Performance

As of 20-Nov-2026, Cellectis’s stock price is $1.00. Its current market cap is $101M with 101M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.00 $1.08 $0.99 - $5.47 $101M 101M 461K -$1.26

Cellectis Financials Summary

As of 30-Sep-2026, Cellectis has a trailing 12-month revenue of $25.2M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 70,771 396,781 11,975 236,295
Revenue 25,168 72,949 41,506 755
EBITDA (80,817) (49,345) (20,740) (96,251)
Net Income (127,376) (67,593) (36,761) (101,059)
Total Assets 213,425 324,720 383,544 334,270
Total Debt 89,076 90,733 91,461 85,056
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Cellectis Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Cellectis‘s full profile, request access.

Request a free trial

Cellectis Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop produc
Drug Discovery
Paris, France
229 As of 2025

Redwood City, CA
 

Chengdu, China
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Cellectis Competitors (85)

One of Cellectis’s 85 competitors is Coherus Oncology, a Formerly VC-backed company based in Redwood City, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Coherus Oncology Formerly VC-backed Redwood City, CA
Polaris Group (Drug Discovery) Formerly PE-Backed Chengdu, China
Northwest Biotherapeutics Corporation Bethesda, MD
Adaptimmune Therapeutics Formerly VC-backed Abingdon, United Kingdom
Valerio Therapeutics Formerly VC-backed Paris, France
You’re viewing 5 of 85 competitors. Get the full list »

Cellectis Patents

Cellectis Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026195675-A1 Mitochondrial base editors Pending 18-Mar-2025
WO-2026046724-A1 Tale protein scaffolds involving fusions of monopartite and bipartite nls Pending 30-Aug-2024
WO-2025181336-A1 Compositions and methods for hbb-editing in hspc Pending 01-Mar-2024
WO-2025168476-A1 Homogenization device Pending 05-Feb-2024
WO-2024246301-A1 Methods for identifying tale base editors off-sites Inactive 02-Jun-2023 C12N15/102
To view Cellectis’s complete patent history, request access »

Cellectis Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cellectis Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Cellectis‘s full profile, request access.

Request a free trial

Cellectis Investments & Acquisitions (4)

Cellectis’s most recent deal was a Corporate with Primera Therapeutics for . The deal was made on 29-Dec-2022.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Primera Therapeutics 29-Dec-2022 Corporate Biotechnology
Cellartis 04-Nov-2011 Merger/Acquisition Biotechnology
Cyto Pulse Sciences 02-Sep-2010 Merger/Acquisition Discovery Tools (Healthcare)
Vectocell Technology 12-Oct-2009 Corporate Asset Purchase Buildings and Property
To view Cellectis’s complete investments and acquisitions history, request access »

Cellectis ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

41.2 | Severe Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Cellectis’s complete esg history, request access »

Cellectis Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Calyxt Roseville, MN 2010

Cellectis FAQs

  • When was Cellectis founded?

    Cellectis was founded in 1999.

  • Where is Cellectis headquartered?

    Cellectis is headquartered in Paris, France.

  • What is the size of Cellectis?

    Cellectis has 229 total employees.

  • What industry is Cellectis in?

    Cellectis’s primary industry is Drug Discovery.

  • Is Cellectis a private or public company?

    Cellectis is a Public company.

  • What is Cellectis’s stock symbol?

    The ticker symbol for Cellectis is ALCLS.

  • What is the current stock price of Cellectis?

    As of 20-Nov-2026 the stock price of Cellectis is $1.00.

  • What is the current market cap of Cellectis?

    The current market capitalization of Cellectis is $101M.

  • What is Cellectis’s current revenue?

    The trailing twelve month revenue for Cellectis is $25.2M.

  • Who are Cellectis’s competitors?

    Coherus Oncology, Polaris Group (Drug Discovery), Northwest Biotherapeutics, Adaptimmune Therapeutics, and Valerio Therapeutics are some of the 85 competitors of Cellectis.

  • What is Cellectis’s annual earnings per share (EPS)?

    Cellectis’s EPS for 12 months was -$1.26.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process